Evidence map›Paper›PMID 37711130›Full record

ReviewCurrent medicinal chemistry2024

Three Decades of Targeting Falcipains to Develop Antiplasmodial Agents: What have we Learned and What can be Done Next?

Jorge Enrique Hernández González, Emir Salas-Sarduy, Lilian Hernández Alvarez, Pedro Alberto Valiente, Raghuvir Krishnaswamy Arni, Pedro Geraldo Pascutti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jorge Enrique Hernández GonzálezMultiuser Center for Biomolecular Innovation, IBILCE/UNESP, São José do Rio Preto, SP, Brazil.ORCID 0000-0002-4770-8677
Emir Salas-SarduyInstituto de Investigaciones Biotecnológicas Dr. Rodolfo Ugalde, Universidad Nacional de San Martín, CONICET, San Martín, Buenos Aires, Argentina.
Lilian Hernández AlvarezMultiuser Center for Biomolecular Innovation, IBILCE/UNESP, São José do Rio Preto, SP, Brazil.
Pedro Alberto ValienteDonnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, Canada.
Raghuvir Krishnaswamy ArniMultiuser Center for Biomolecular Innovation, IBILCE/UNESP, São José do Rio Preto, SP, Brazil.
Pedro Geraldo PascuttiLaboratório de Modelagem e Dinâmica Molecular, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, RJ, Brazil.

Funding

Sao Paulo Research Foundation Grants 22/03901-8 and 20/08615-8.
6 · The paper itself

Abstract

Malaria is a devastating infectious disease that affects large swathes of human populations across the planet's tropical regions. It is caused by parasites of the genus Plasmodium, with

Indexed as

AntimalarialsCysteine EndopeptidasesCysteine Proteinase InhibitorsPlasmodium falciparumAnimalsHumansAntimalarialsCysteine EndopeptidasesCysteine Proteinase Inhibitorsfalcipainfalcipain 2drug discoveryFalcipain 2falcipain 3inhibitors.malariaPlasmodium falciparum

Identifiers

PMID37711130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.